Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer

M. Gharaibeh, A. McBride, J Lyle Bootman, Ivo L Abraham

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Background:The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses of NAB-P+GEM from the payer perspective have not been conducted for the UK.Methods:A Markov model simulating the health outcomes and total costs was developed to estimate the life years gained (LYG) and quality-adjusted life years gained (QALY) and incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) for patients with MPC in a base case and in a probabilistic (PSA) sensitivity analysis. Total cost included the cost of supportive care medications, administration, chemotherapy, disease monitoring, and adverse reactions; and was discounted at 3.5% per year. A full lifetime horizon and third party payer perspective was chosen.Results:The total cost of NAB-P+GEM was £5466 higher than the cost for GEM. Respectively, LYGs were 0.97 vs 0.79 and QALYs were 0.52 vs 0.45, with ICER of £30 367/LYG and ICUR of £78 086/QALY, confirmed by PSA.Conclusions:The superior survival efficacy of NAB-P+GEM over GEM in the management of MPC is associated with positive cost-effectiveness and cost-utility.

Original languageEnglish (US)
Pages (from-to)1301-1305
Number of pages5
JournalBritish Journal of Cancer
Volume112
Issue number8
DOIs
Publication statusPublished - Apr 14 2015

    Fingerprint

Keywords

  • cost-effectiveness
  • cost-utility
  • gemcitabine
  • metastatic disease
  • nab-paclitaxel
  • pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this